The medication, developed by the Vector State Research Centre of Virology and Biotechnology, is a peptide-based drug that relies on a promising synthetic platform. It consists of artificially synthesised short fragments of viral proteins – peptides, through which the immune system learns how to recognise and then neutralise the virus.